Novel PD-L1 Small-Molecule Inhibitors Advancing Cancer Immunotherapy
Small-molecule PD-L1 inhibitors offer a promising avenue for expanding cancer immunotherapy. Our review highlights key advances and introduces novel small-molecule PD-L1 inhibitors with strong potential for future development, particularly in combination regimens.
Authors
- Annoor Awadasseid (ORCID: https://orcid.org/0000-0002-1216-8244)
- Feng Zhang (ORCID: https://orcid.org/0000-0002-6751-0377)
- Wen Zhang (ORCID: https://orcid.org/0000-0002-3247-9672)
- Yanling Wu (ORCID: https://orcid.org/0000-0001-9075-3337)
- Mengda Wu
- Yanhua Song
Institutions
- Zhejiang Yongning Pharma (China) (CN)
- Zhejiang Center for Disease Control and Prevention (CN)
- Zhejiang Chem-tech Group (China) (CN)
- Zhejiang University of Technology (CN)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2025-10-03
- DOI
- https://doi.org/10.2174/0118715206393267250912114756
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05